Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Wins Part D Cholesterol Therapy Formulary Battle; Lipitor In Retreat?

Executive Summary

Merck appears to be the big winner in the Medicare Part D formulary placement battle for cholesterol-lowering therapies, according to an analysis of plan formularies conducted by the "The Pink Sheet."

You may also be interested in...



Zocor Falls Off Formularies As Part D Plans Shift Patients To Generic Statins

Zocor dropped quickly off of Part D formularies after having enjoyed wide preferred coverage in 2006, an analysis of 2007 Part D basic plan coverage of the statin group of cholesterol-lowering drugs indicates

Zocor Falls Off Formularies As Part D Plans Shift Patients To Generic Statins

Zocor dropped quickly off of Part D formularies after having enjoyed wide preferred coverage in 2006, an analysis of 2007 Part D basic plan coverage of the statin group of cholesterol-lowering drugs indicates

Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers

Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel